Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen LUMAKRAS / LUMYKRAS (sotorasib by Year
LUMAKRAS / LUMYKRAS (sotorasib — KRAS G12C Non-Small Cell Lung Cancer) — Worldwide reported sales growth YoY (%) (%)
Amgen LUMAKRAS / LUMYKRAS (sotorasib: 4.0% in FY2025, down 21.0 pts from a year earlier.
Where the FY2025 figure comes from
“|| LUMAKRAS ® /LUMYKRAS ™ | 211 | 152 | 363 | 350 | 4%”
Source: Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Reported in Form 8-K Product Sales Detail by Product and Geographic Region.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | LUMAKRAS / LUMYKRAS (sotorasib — KRAS G12C Non-Small Cell Lung Cancer) — Worldwide reported sales growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4.0% | -21.0 pts | Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 25.0% | +27.0 pts | Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | -2.0% | – | Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗ |
Cite this data
StockData. (2026). Amgen LUMAKRAS / LUMYKRAS (sotorasib (%), annual FY2023–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-lumakras-yoy
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.